Home › Research › Topics › randomized
randomized
804 studies tagged randomized, dated 1986-01-01 to 2026-09-22. Bibliography: BibTeX (.bib) · RIS (.ris)
Newest in this topic
- Ceperognastat in Early Symptomatic Alzheimer Disease: A Randomized Clinical Trial 2026-09-22
- Varenicline as a Repurposable Drug Candidate for ADRD Prevention 2026-09-20
- Antihypertensive Medication Class and Incident Alzheimers Disease and Related Dementias: External Replication Across Two Independent Healthcare Data Sources-the Vanderbilt EHR Synthetic Derivative and US Medicare Claims 2026-09-17
Studies
804 studies carry this tag.
Date range
1986 to 2026
Top journals
- Neurology 66
- The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 35
- JAMA 24
- JAMA neurology 23
- Alzheimer's research & therapy 21
333 journals in all.
Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.
-
Our comprehensive search yielded 5 eligible studies.
-
Addressing the need for rigorous longitudinal data for the effectiveness of music therapy in people with and at risk for developing AD, this trial aims to enhance knowledge regarding cost-effective interventions with potentially high clinical applicability.
-
Our results depict that 5 Hz rTMS of the bilateral cerebellum is a promising, non-invasive treatment of cognitive dysfunction in AD patients.
-
These findings suggest that at current expected prices, neither aducanumab nor donanemab would be cost-effective for early AD in the US.
-
Before donanemab was approved, researchers built a computer model simulating lifetime outcomes for Alzheimer's patients to estimate whether aducanumab and donanemab were reasonably priced for the health benefit they provide.
-
To estimate the risk of ischaemic stroke associated with antidopaminergic antiemetic (ADA) use.
-
Anodal tDCS+CS delays cognitive decline (ADAS-cog change) to a greater extent than sham tDCS+CS (-3.4±1.1 vs. -1.7±0.4; p=.03).
-
A person affected by Alzheimer's disease (AD) gradually loses the ability to perform activities of daily living and becomes dependent on caregivers, thereby having a negative impact on the caregivers' quality of life.
-
The author panel systematically reviewed available clinical trial data detailing aducanumab use in individuals with early symptomatic Alzheimer disease.
-
Salvia species have a longstanding traditional culinary use, mostly being consumed in the Mediterranean diet as a common herb added to food.
-
PBM treatment significantly improved the typical AD pathologies of memory loss, amyloid plaques, tau hyperphosphorylation, neuronal degeneration, spine damage, and synaptic loss.
-
49/100
Aducanumab was granted accelerated approval with a conflicting evidence base, near-unanimous Food and Drug Administration Advisory Committee vote to reject approval, and a widely criticized launch price of $56,000 per year.
-
Alzheimer's disease is a progressive, irreversible, and fatal disease for which accumulation of amyloid beta is thought to play a key role in pathogenesis.
-
We review the implications of the recently approved aducanumab amyloid-β immunotherapy for treating Alzheimer disease with comorbid cerebral amyloid angiopathy.
-
The two groups' baseline characteristics, including age, sex, mean length of education, and disease duration, were comparable, as were their baseline Mini-Mental State Examination scores.
-
This study aimed to examine the therapeutic mechanism of the benefit-finding therapeutic (BFT) intervention that used cognitive reappraisal and alternative thinking to construct positive aspects of caregiving (PAC), in a cluster-randomized controlled trial for Alzheimer caregivers.
-
Of 54 adults assessed for eligibility, 11 did not meet study criteria, and 9 declined to participate.
-
Of 200 participants, 99 were assigned to methylphenidate and 101 to placebo.
-
The current study aimed to provide data on the effectiveness of the 10 cm2 rivastigmine patch in patients with Alzheimer's disease (AD) in a real-world setting in Taiwan.
-
This cluster randomized clinical trial found that despite high adherence to the training, a multicomponent intervention promoting goal-directed care for suspected UTIs and LRIs did not significantly reduce antimicrobial use among nursing home residents with advanced dementia.
-
These results indicate that trans-resveratrol has potential neuroprotective roles in the treatment of moderate to mild AD and that its mechanism may involve a reduction in the accumulation and toxicity of Aβ in the brain of patients, thereby reducing neuroinflammation.
-
Overall, the study with the same protocol is going as expected with no serious AE or any major protocol deviation.
-
As a result of the PLST training, there was a decrease in the behavioural problems of Alzheimer's patients, along with a decrease in the care burden of the caregivers and an increase in their care satisfaction.
-
Accelerated approval of aducanumab for mild Alzheimer's by the U.S. Food and Drug Administration on June 7, 2021, has generated substantial medical, scientific, and ethical controversy.
-
On June 7, 2021, the FDA granted accelerated approval to aducanumab (Aduhelm), the first new Alzheimer's drug approved since 2003 and the first ever approved for a mechanism thought to modify disease course.
-
At randomization, the mean age is 72, 50% female, 77% with CDR-global score 0.5, and mean MMSE score 23.8.
-
BAN2401-G000-201 did not meet the 12-month primary endpoint.
-
Aducanumab is an anti-amyloid-β (Aβ) antibody that achieved reduced amyloid pathology in Alzheimer's disease (AD) trials; however, it is controversial whether it also improved cognition, which has been suggested would require a sufficiently high cumulative dose of the antibody in the brain.
-
These findings suggest that benzoate treatment may improve cognitive function in women with later-phase dementia.
-
Patients with Alzheimer dementia from the Swedish Dementia Registry starting on ChEIs within 3 months of the dementia diagnosis were included and compared to nontreated patients with Alzheimer dementia.
-
A significant drug-placebo difference on the ADAS-Cog12 favoring GV-971 was present at each measurement time point, measurable at the week 4 visit and continuing throughout the trial.
-
In patients with early Alzheimer's disease, donanemab resulted in a better composite score for cognition and for the ability to perform activities of daily living than placebo at 76 weeks, although results for secondary outcomes were mixed.
-
change from baseline in Preclinical Alzheimer Cognitive Composite score.
-
This is the first randomized trial to investigate the impact of a ketogenic diet in patients with uniform diagnoses of AD.
-
Vascular cognitive impairment (VCI) describes a broad spectrum of cognitive impairments caused by cerebrovascular disease, ranging from mild cognitive impairment to dementia.
-
Improvements in the aspects evaluated are expected in the IG compared to CG.
-
Recent trials of repetitive transcranial magnetic stimulation (rTMS) have reported encouraging results for improving or stabilizing cognition in patients diagnosed with Alzheimer dementia.
-
We found that both Adu and SUS reduced the total plaque area in the hippocampus to a similar degree, with no additive effect in the combination treatment (SUS+Adu).
-
40/100
According to the FDA, aducanumab (Aduhelm), the recently approved anti-Alzheimer drug, reduces the level of cerebral amyloid plaques-a hallmark finding in patients with Alzheimer's disease-and this will result in a reduction in clinical decline.
-
This trial that enlist the support of private enterprises will lead to the creation of new services for dementia prevention as well as to verify the effectiveness of multi-domain interventions for dementia prevention.
-
EGb 761 ® is currently recommended in multiple guidelines for the symptomatic treatment of MCI.
-
Amyloid-β (Aβ) aggregated forms are highly associated with the onset of Alzheimer's disease (AD).
-
Suboptimal sleep causes cognitive decline and probably accelerates Alzheimer's Disease (AD) progression.
-
26/100
Anticholinergic medications (ACh) are frequently prescribed to older adults despite being associated with impaired physical functioning.
-
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by dementia, memory impairment, cognitive dysfunction, and speech impairment.
-
Low-dose aspirin did not prevent depression in this large-scale study of otherwise healthy older adults.
-
The treatment of Alzheimer's disease (AD) in the field of non-pharmacological interventions is a challenging issue, given the limited benefits of the available drugs.
-
Baseline assessments were conducted on 128 participants.
-
47/100
Alzheimer's disease (AD) is a progressive, late-onset dementia with no effective treatment available.
-
No clinically important adverse events were associated with treatment.
From across this tag
9 of the 795 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 9. The same 9 appear here every time.
- A Psychosocial Intervention for Supporting Informal Caregivers of Older People With Alzheimer Disease: Protocol for the InnFamiglia Randomized Controlled Trial
- Statins Use in Alzheimer Disease: Bane or Boon from Frantic Search and Narrative Review
- Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease
- Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group
- Modified titration of donanemab reduces ARIA risk and maintains amyloid reduction
- Effect of SSRIs on clinical progression in amnestic mild cognitive impairment stratified by Alzheimer's disease pathology
- Effect of long-term omega-3 supplementation and a lifestyle multidomain intervention on intrinsic capacity among community-dwelling older adults: Secondary analysis of a randomized, placebo-controlled trial (MAPT study)
- Medication development for agitation and aggression in Alzheimer disease: review and discussion of recent randomized clinical trial design
- Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US